TriSalus Life Sciences

Update in progress

TLSI (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

TriSalus Life Sciences develops and commercializes drug delivery technology and immuno-oncology therapies to improve outcomes for patients with hard-to-treat liver and pancreatic cancers in the United States. Its Pressure-Enabled Drug Delivery platform includes the TriNav infusion system used in liver tumor embolization, plus a Pancreatic Retrograde Venous Infusion device in Phase 1. It also develops nelitolimod in Phase 1 for multiple cancers. Founded 2009, based in Westminster, Colorado.

Company score

Sentiment: 0.02; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.07; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.00; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive